I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diabetes mellitus (DM) is associated with risk of cardiovascular diseases, which cannot be fully justified by important risk factors such as hyperglycemia,\[[@ref1]\] hypertension,\[[@ref2]\] and dyslipidemia.\[[@ref3]\] Among all risk factors, homocysteine (Hcy) is recognized as an independent,\[[@ref4]\] and potentially modifiable,\[[@ref5]\] risk factor that may be strongly linked to cardiovascular prognosis in Type 2 diabetes.\[[@ref6]\] It can also be a determinant of microalbuminuria and diabetic retinopathy.

Hcy is produced during the demethylation of methionine. It is normally metabolized by two pathways, remethylation and transsulfuration. Remethylation acts as a catalyst for methionine synthase. In this reaction, 5-methyltetrahydrofolate is a methyl group donor and Vitamin B~12~ is a cofactor.

Several studies found decreased serum Vitamin B~12~ level among metformin-treated diabetes patients\[[@ref7]\] probably due to malabsorption.\[[@ref8]\] Hence, during metformin treatment, Hcy level might increase, but data on this issue are contradictory.\[[@ref9][@ref10]\]

With this idea in mind, we conducted a study at B.R. Singh Hospital, Kolkata, among the Type 2 diabetic patients who are on metformin for at least 2 years but not more than 3 years after they were first detected with diabetes and compared them with patients not on metformin for the same duration. The effects of metformin treatment on serum levels of Hcy, Vitamin B~12~ and folate level in patients with Type 2 diabetes were studied.

Aims and objectives {#sec2-1}
-------------------

To study the blood level of Vitamin B~12~, folic acid, and Hcy in metformin-treated early Type 2 DMTo study the evidence of peripheral neuropathy in metformin-treated early Type 2 DM.

M[ETHODOLOGY]{.smallcaps} {#sec1-2}
=========================

A hospital-based, comparative, descriptive study was conducted in the Department of Medicine, B.R. Singh Hospital, Kolkata, during August 2010--June 2012. A total of ninety patients were recruited for the study after proper screening and sampling. Systematic sampling procedure was used as sampling. Here, three groups were created and they are as follows. Group A (20 patients): Patients on tablet metformin with other oral hypoglycemic agent (OHA) treatment, Group B (35 patients): Patient on tablet metformin, and Group C (35 patients): Patient on other OHA than metformin. Patients were diagnosed by the American Diabetes Association (ADA) guidelines. All the patients were properly examined and related tests were conducted according to the protocol.

Nerve conduction velocity (NCV) tests were performed using RMS EMG EP MARK II 2 CH Machine kit in all patients, and results were assessed according to the ADA diabetic neuropathy protocol. The NCV studies were carried out through device. Median, ulnar, peroneal nerve conduction studies, F-wave, and median, ulnar, and sural NCVs were recorded at room temperature maintained at 22--24°C. Standard NCVs were used.

Polyneuropathy types were described as either demyelinating or axonal.

Demyelinating neuropathy was diagnosed as:

A reduction of conduction velocities of at least 40% in at least 2 motor or 1 sensory nervesProlonged terminal motor latenciesPartial conduction blockAn absent F-wave or prolonged F-wave latencies in 2 or more motor nerves.

Axonal neuropathy was diagnosed as:

Conduction velocities were normalThe size of compound muscle action potential and sensory nerve action potentials were decreased in at least two motor nerves and one sensory nerve.

Inclusion criteria for patients:

Patient detected with Type 2 DM with disease duration \<5 yearsPatients getting treatment for Type 2 DM not more than 3 yearsPatients getting metformin up to 2 g per day.

Exclusion criteria for patients:

Patients suffering from diabetes more than 5 yearsPatients who are strictly on vegetarian dietPatients suffering from multiple complications of Type 2 DM and overt diabeticPatients suffering from kidney, liver, thyroid diseasesPatients with alcohol abuse, smokerFamily history of peripheral nerve diseaseHistory of malignanciesHistory of toxic exposure and drug exposure causing peripheral neuropathyPatients with autoimmune disorder or pregnancyUnconscious and severely ill patientsPatients who were mentally impaired and/or unable to give consent.

An informed consent based on an appreciation and understanding of the study and its procedures was taken from each patient, and the study was approved by the Institutional Ethical Committee.

Data were collected and diagram was prepared on the basis of baseline demographic parameters and the statistical analysis was done using SPSS version 11.5 (SPSS Inc, headquartered in Chicago, IL, USA) for ANOVA, *post hoc* test, and Chi-square test keeping α level to 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total ninety diabetes patient were followed. Among them, twenty patients belonged to Group A (patients on tablet metformin with other OHA treatment), 35 patients belonged to Group B (patient on tablet metformin), and the rest 35 patients belonged to Group C (patient on other OHA than metformin).

The mean ± standard deviation (years) of age of Groups A, B, and C were 49.45 ± 5.41, 50.46 ± 7.48, and 50.46 ± 4.96, respectively. Totally, 34 females and 56 males participated in the study \[[Table 1](#T1){ref-type="table"}\].

###### 

Participants, treatment and Bio-chemistry related characteristic of three groups

![](IJEM-20-631-g001)

The serum Vitamin B~12~ level is much higher among patients who did not take tablet metformin. This difference is statistically significant by ANOVA test. The level of folic acid is significantly lower among Group B than other groups. It is also observed that 54.28% of Group B patients have neuropathy, which is much higher than Group A (35%) and Group C (28.57%) \[[Table 1](#T1){ref-type="table"}\]. Sensory neuropathy is only present among of them \[[Table 2](#T2){ref-type="table"}\].

###### 

Neuropathy present in study population
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In Chi-square test, a trend of association observed that metformin users were more prone to develop sensory neuropathy \[[Table 3](#T3){ref-type="table"}\].

###### 

Chi-square tests
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*Post hoc* study shows that there is significant lowering in the level of Vitamin B~12~ and Hcy level in patients who are using only metformin for controlling blood sugar than who are using metformin with other OHD and who are controlling it without metformin. Plasma folic acid level has insignificant variation in metformin user and not metformin user groups; this may be due to their food habit \[[Table 4](#T4){ref-type="table"}\].

###### 

*Post hoc* test of plasma Vitamin B~12~, folic acid, homocysteine level
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These significant differences were observed among three groups related with body mass index (BMI), postprandial blood sugar (PPBS), and duration of therapy by *post hoc* test \[[Table 5](#T5){ref-type="table"}\].

###### 

*Post hoc* test of body mass index, postprandial blood sugar, and duration of therapy

![](IJEM-20-631-g005)

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Metformin, an oral biguanide, has been used as antidiabetic agent for more than 40 years. The UK Prospective Diabetes Study recommends lifestyle modification and metformin to be the first-line therapy for Type 2 DM. However, long-term therapy with metformin was shown to decrease the Vitamin B~12~ level and manifested as peripheral neuropathy, cognitive impairment, subacute degeneration of cord with macrocytic anemia.\[[@ref8][@ref9][@ref11][@ref12][@ref13]\] Even short-term therapy with metformin can cause a decrease in serum Vitamin B~12~ and folic acid level and an increase in Hcy level.\[[@ref11]\] In our study, we found that study population using only metformin (54.28%) is prone to develop peripheral neuropathy than study population with no metformin (28.57%) and metformin with other drugs (35%). There is significant low level of plasma Vitamin B~12~ associated with only metformin therapy (mean 306.314 pg/ml), than without metformin (mean 627.543 pg/ml) and metformin with other drugs (mean 419.920 pg/ml); patients using metformin either as alone or along with other drug have a trend to develop Vitamin B~12~ deficiency. There is insignificant low level of plasma folic acid in only metformin user (mean 16.47 ng/ml) than in no metformin (16.81 ng/ml) and metformin with other drugs (22.50 ng/ml); this may be due to the fact that all of our patients are having good dietary advice and taking a good amount of green leafy vegetables. There are significant high levels of Hcy in population with only metformin therapy (mean 17.35 µmol/L) and population taking metformin with other drugs (mean 16.99 µmol/L) than in population not taking metformin (mean 13.22 µmol/L). From our study, it is seen that BMI is better controlled in patients who are taking metformin only for DM control than other two groups. This may be due to the fact that some of our patients are on thiazolidinediones which can cause an increase in body weight\[[@ref14]\] although there is insignificant BMI variation in metformin and no metformin group. From our study, it is seen that PPBS is well controlled in only metformin user group than in other two groups of patients; from this result, we may say that metformin use can control PPBS well, along with other groups of drugs such as α-glucosidase inhibitors. In our study, patients with Vitamin B~12~ deficiency presented clinically either with symptoms of altered joint position sense, large fiber neuropathy, or asymptomatic.

Tomkin *et al*. showed that metformin is one of the pharmacological causes of Vitamin B~12~ deficiency, and it is evident that from their study, 10% to 30% patients developed evidence of Vitamin B~12~ deficiency.\[[@ref12]\] Pflipsen *et al*. in another study showed a 22% prevalence of Vitamin B~12~ in metformin-treated DM.\[[@ref15]\] In our study, population who were taking only metformin have a lower mean Vitamin B~12~ level than population taking other drugs with metformin and population who are not taking metformin at all. Wile and Toth showed in their study that more than 6 months treatment with metformin could cause a low level of Vitamin B~12~ and a high level of Hcy associated with peripheral neuropathy.\[[@ref16]\] In our study also, there is significant lower level of Vitamin B~12~ and higher level of Hcy associated with peripheral neuropathy in metformin-treated patients.

Liu *et al*. reported two cases of very long-term treatment (20 and 8 years, respectively) with metformin therapy associated with advanced neurological and hematological side effects due to metformin-induced Vitamin B~12~ deficiency.\[[@ref17]\] In our study, even patients with approximate 2 years of metformin therapy showed evidence of peripheral neuropathy.

Adams *et al*. showed in their study that 30% of 46 patients undergoing biguanide therapy developed Vitamin B~12~ malabsorption, which resolved in half on stopping the drug.\[[@ref18]\] In our study, 54.28% of patients taking only metformin therapy and 35% of patients taking metformin along with other drugs for controlling their Type 2 DM developed Vitamin B~12~ deficiency, whether this could be reversible we do not know as our study design is a cross-sectional study.

Reinstatler *et al*. in their study showed that there was a significant low value of Vitamin B~12~ in persons using metformin for their Type 2 DM treatment. Shortcoming of this study is that they were not using any functional biomarker for Vitamin B~12~ such as methylmalonic acid or Hcy.\[[@ref19]\] In our study, we also found similar results, but we have used Hcy level as functional biomarker. Our sample size was not based on a predetermined power analysis though our study populations were selected randomly.

Chen *et al*. in their study measured holotranscobalamin and methylmalonic acid which are more specific and sensitive markers of Vitamin B~12~ deficiency and showed that there was Vitamin B~12~ deficiency in metformin-treated Type 2 DM.\[[@ref20]\] This is a shortcoming of our study that we could not measure both holotranscobalamin and methylmalonic acid, but we do conclude that even 2 years continuous therapy with metformin can cause Vitamin B~12~ deficiency.

Wulffelé *et al*. in their 16-week comprehensive short-term metformin treatment study showed that there was decrease in the Vitamin B~12~ and folic acid level and increase in the Hcy level even with short-term therapy with metformin.\[[@ref11]\] In our study, decreased Vitamin B~12~ level and increased Hcy level noted in metformin -- treated population. But folate level difference was not so much high than the other OHA treated population with metformin treated population. This may be due to that our patients counseled about dietary folate supplementation through green leafy vegetable intake. From our study, no one should interpret that metformin is not a good choice of drug to start with rather it is desirable to estimate an annual Vitamin B~12~ for monitoring deficiency state of the same.

Pierce *et al*. and Bell recommended this in their individual studies.\[[@ref21][@ref22]\] None of our patients show any hematological evidence of Vitamin B~12~ and folic acid deficiency, i.e. macrocytic anemia; this may be due to the fact that we enroll only those patients taking metformin for \<3 years, and therefore, we recommend a long-term regular follow-up of these patients with complete hemogram.

From our study, another interesting fact we also come across along with the Vitamin B~12~, folic acid, Hcy level that patients using metformin only for controlling their plasma glucose have their PPBS lower than other two groups of patients. Lund *et al*. in their study showed that postprandial glucose can also be well controlled with use of metformin.\[[@ref23]\]

Although India is the diabetic capital, our study population is very small as we exclude the patients who were suffering for a long (\>5 years) duration. Diabetes itself on long duration can cause sensory neuropathy mainly involving small fibers causing tingling--burning sensations.\[[@ref24][@ref25]\]

Our study had certain practical limitations. We could not perform nerve biopsy which also suggests annual screening of the pathological gold standard for determination of the presence and types of neuropathy. Therefore, confirmation of the electrophysiological findings could not be done. This was because very few patients gave consent for an invasive procedure like nerve biopsy and lack of expertise needed for biopsy and preparation and interpretation of results. A multicentric study would have made the patient population more heterogeneous and would have increased the power of the study. As the study was undertaken in a tertiary care referral hospital, it was very difficult to find patients without a prescription of metformin, and most of our patients are in advanced stages of Type 2 DM so that we were restricted our study population in small groups. As we did not follow up our patients with an increased Hcy level, we cannot comment about the cardiovascular effect of increased level of Hcy in the long run.

Due to lack of follow-up in this study, we are not able to show that Vitamin B~12~ supplementation or change over to other antidiabetic can improve the condition as evident in case report by Kumthekar *et al*.\[[@ref26]\] At the end of this discussion, we can conclude by saying that metformin due to its cost-effectiveness and worldwide availability, surely, the first choice of antidiabetic in treatment of Type 2 DM. It induces peripheral neuropathy by initiating Vitamin B~12~ deficiency through probably blocking its absorption through calcium-mediated channel in the intestine. For proper monitoring of deficiency status, it is desirable that an annual Vitamin B~12~, folic acid, and Hcy level estimation can predict the after coming event of peripheral neuropathy, which is a preventable and reversible cause.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

Metformin, oral biguanide, is the first choice of medication to control plasma glucose levels along with lifestyle modification. It is also cost-effective in a country like us. However, initiation of metformin therapy even early and for short duration can induce Vitamin B~12~, folic acid deficiency and an increase in plasma Hcy level, which can precipitate peripheral neuropathy. From our study, we observed that with metformin, BMI and PPBS were well maintained comparing combination therapy with and without metformin. Thus, it should not be interpreted from our study that it is not so good agent to start with initial management of Type 2 DM rather start with a supplementation of Vitamin B~12~ along with it. This is also desirable that one should observe Vitamin B~12~ level annually for monitoring of patients on long-term therapy.

At the end our study, we recommend further studies in:

Follow-up study of the patient with peripheral neuropathy if they can improve with Vitamin B~12~ supplementationFurther cross-over study to look for any improvement in neuropathy status with change of antidiabetic therapy, to observe dose-dependent changes in NCV study in metformin-treated patients, and to observe dose-dependent changes in Vitamin B~12~, Hcy level in metformin-treated patients.
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